Annals of Nuclear Medicine

, 25:520

99mTc-GSA SPECT analysis was clinically useful to evaluate the effect of interferon in a patient with interferon non-responsive chronic hepatitis C

  • Rika Ishii
  • Hitoshi Togashi
  • Akiko Iwaba
  • Chikako Sato
  • Hiroaki Haga
  • Mai Sanjo
  • Kazuo Okumoto
  • Yuko Nishise
  • Jun-itsu Ito
  • Hisayoshi Watanabe
  • Koji Saito
  • Akio Okada
  • Kazuei Takahashi
  • Takafumi Saito
  • Sumio Kawata
Case Report
  • 92 Downloads

Abstract

We describe a 62-year-old woman with advanced chronic hepatitis C who showed no response to low-dose long-term interferon-beta monotherapy (3 MU, three times a week). The interferon monotherapy was continued for 2 years and 9 months. Despite this lack of response to interferon, the patient’s clinical course was good and liver function assessed by 99mTc-galactosyl human serum albumin single photon emission computed tomography (99mTc-GSA SPECT) analysis improved significantly. Improvement of the data obtained by 99mTc-GSA SPECT analysis justified continuation of the treatment. 99mTc-GSA SPECT analysis was clinically useful to evaluate the effect of interferon in a patient with interferon non-responsive chronic hepatitis C, despite a lack of reduction of the ALT level and HCV-RNA titer.

Keywords

Chronic hepatitis C Interferon non-responder 99mTc-GSA SPECT 

References

  1. 1.
    Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance inteferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999;117:1164–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, et al. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: a pilot study. Hepatol Res. 2007;37:490–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J Med Virol. 2008;80:1363–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. New Engl J Med. 2008;359:2429–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Sugahara K, Togashi H, Takahashi K, Onodera Y, Sanjo M, Misawa K, et al. Separate analysis of asialoglycoprotein receptors in the right and left hepatic lobes using Tc-99m-GSA SPECT. Hepatology. 2003;38:1401–9.PubMedGoogle Scholar
  9. 9.
    Tanabe J, Izawa A, Takemi N, Miyauchi Y, Torii Y, Tsuchiyama H, et al. Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects. Immunology. 2007;122:562–70.PubMedCrossRefGoogle Scholar
  10. 10.
    Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40:8–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method. J Gastroenterol. 2000;35:105–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine. 2006;33:121–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Izuma M, Kobayashi K, Shiina M, Ueno Y, Ishii M, Shimosegawa T, et al. In vitro cytokine production of peripheral blood mononuclear cells in response to HCV core antigen stimulation during interferon-beta treatment and its relevance to sCD8 and sCD30. Hepatol Res. 2000;18:218–29.PubMedCrossRefGoogle Scholar
  14. 14.
    Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu Y, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology. 2003;38:859–68.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2011

Authors and Affiliations

  • Rika Ishii
    • 1
  • Hitoshi Togashi
    • 1
    • 2
  • Akiko Iwaba
    • 3
  • Chikako Sato
    • 1
  • Hiroaki Haga
    • 1
  • Mai Sanjo
    • 1
  • Kazuo Okumoto
    • 1
  • Yuko Nishise
    • 1
  • Jun-itsu Ito
    • 1
  • Hisayoshi Watanabe
    • 1
  • Koji Saito
    • 1
  • Akio Okada
    • 4
  • Kazuei Takahashi
    • 4
  • Takafumi Saito
    • 1
  • Sumio Kawata
    • 1
  1. 1.Department of GastroenterologyYamagata University Faculty of MedicineYamagataJapan
  2. 2.Yamagata University Health Administration CenterYamagataJapan
  3. 3.Department of Pathological DiagnosticsYamagata University Faculty of MedicineYamagataJapan
  4. 4.Department of RadiologyYamagata University Faculty of MedicineYamagataJapan

Personalised recommendations